Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T14:30:21.103Z.
Consensus retrieved: 2026-10-06T08:23:00.613Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T14:30:21.103Z.
Quote observation: 2026-10-06T14:30:04.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: bd475241593d5c58f7737f650220a879a7f67ee05652ed27eb0102460b642cb0
Forward PE Ratio (N/A) = Dated Quote Price ($1.93) / Consensus Forward EPS ($-1.85)
FORWARD PE RATIO
N/A
Acrivon Therapeutics, Inc. Common Stock
Market Cap
$82.61M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Acrivon Therapeutics, Inc. Common Stock (ACRV) | $82.61M | N/A |
| MediciNova, Inc. (MNOV)vs › | $82.20M | N/A |
| LENSAR Inc (LNSR)vs › | $81.98M | N/A |
| Citius Oncology, Inc. (CTOR)vs › | $81.83M | 8.80 |
| Humacyte, Inc. (HUMA)vs › | $84.10M | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.13M | N/A |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $84.15M | N/A |
| Conexeu Sciences Inc. (CNXU)vs › | $85.15M | N/A |
| Pulmonx Corporation (LUNG)vs › | $79.62M | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $86.25M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.93, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.85 | $-2.02 – $-1.59 | 5 | n/m |
| 2027-12-31 | $-1.66 | $-2.48 – $-1.01 | 5 | n/m |
| 2028-12-31 | $-1.28 | $-2.22 – $-0.75 | 5 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
